SEC Form 4 · accession 0001209191-15-008475
MYLAN INC. · MYL
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 29, 2015 | M | 3,609 | $0.00 | A | 29,660 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2 | $0.00 | Jan 29, 2015 | M | 3,609 | D | Jan 29, 2015 | — | Common Stock | 3,609 | 0 | D |
Explanation of responses
- F1Represents acquisition of shares of Mylan common stock upon vesting of RSUs.
- F2Each RSU represents the right to receive one share of Mylan common stock. The RSUs were granted on April 11, 2014.
Remarks
The transactions described on this Form 4 are described in the proxy statement filed by Mylan Inc. ("Mylan") on December 24, 2014 and the Form 8-K filed by Mylan on November 5, 2014. In connection with the proposed acquisition (the "Transaction") by a new public company organized in the Netherlands of both Mylan and Abbott Laboratories' non-U.S. developed markets specialty and branded generics business, Mylan's Board of Directors determined, effective November 4, 2014, that the vesting of all unvested stock options, restricted stock units ("RSUs"), and performance restricted stock units granted to directors and executive officers as part of Mylan's ordinary course annual equity compensation program (other than incentive stock options and the options granted in 2014) would be accelerated prior to the Transaction.